🔥Continued, More Clinically Meaningful data in #SSc #ILD from #Nintedanib in >52 wk SENSCIS & SENSCIS-ON(open-label ext)#ACR21 Dr Distler ✨MMF likely to stay 1st line, then Nintedanib ❓Is it time for MMF + Antifibrotic upfront?? Await SLS-III;Data so far seems supportive https://t.co/JWXMlsJgmc

#ACR21 Abs#1367. Scleroderma pts with absent contractility (AC) associated with diffuse cutaneous disease, cardiac involvement, more severe Raynaud's. ⭐️14/67 AC pts died during study (21%), none without AC ⭐️15/16 Ro52+ pts had AC (p=0.06) https://t.co/GAuOiV5ScC @Rheumnow

• https://bit.ly/3C8u5Ul

#ACR21 #pedsrheum juvenile localized scleroderma Polypositive profile 3 or more autos correlated with more severe skin score, more activity https://t.co/vVXV4jjLvG

✨Great Pearls when screening patients for clinically suspect #Scleroderma or #Juvenile #Dermatomyositis 📌 Don’t Stop Work Up at Negative ANA if strongly suspect SSc 📌 #Myositis Specific Antibodies have different phenotypes in kids than adults (MDA-5, TIF-1g, NXP-2) #ACR21 https://t.co/KrkkzA5bkV

Clinical Pearl at #ACR21 by Dr. John Stone: ⭐️Patients w/ RNAPIII positive SSc do not always have puffy hands, Raynaud's phenomenon, or ANA positivity! #ACRBest @RheumNow @SChatterjee https://t.co/9J6OBibi4l